Market cap
$478.7M

REGENXBIO Inc. (RGNX) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for RGNX, including 4 insider trades, 2 earnings updates and 2 SEC filings. The most recent was published Nov 10, 2026.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

RGNX rankings

Financial highlights

Full financials
Revenue, TTM
$153.91M
Revenue growth
-4.6%
Net income, TTM
-$175.23M
Net margin
-113.9%
Free cash flow, TTM
-$154.80M
Cash
$95.80M

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

News · 26 weeks60+150%
2026-05-24: 02026-05-31: 122026-06-07: 02026-06-14: 02026-06-21: 22026-06-28: 42026-07-05: 32026-07-12: 62026-07-19: 12026-07-26: 02026-08-02: 72026-08-09: 02026-08-16: 02026-08-23: 62026-08-30: 22026-09-06: 12026-09-13: 02026-09-20: 22026-09-27: 02026-10-04: 12026-10-11: 32026-10-18: 02026-10-25: 12026-11-01: 82026-11-08: 12026-11-15: 0
2026-05-242026-11-15
Mix2590d
  • Insider8(32%)
  • Other7(28%)
  • SEC Filings6(24%)
  • Earnings2(8%)
  • Leadership1(4%)
  • Analyst1(4%)
Activity · 52 weeks10661 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

RGNX FAQ

11 questions
  • What does REGENXBIO Inc. do?
    REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II...
  • What is the latest news on RGNX?
    In the last 30 days Quantisnow tracked 10 wire items for RGNX: 4 insider trades, 2 earnings updates, 2 SEC filings and 1 press release or news item. The most recent was published on November 10, 2026.
  • What is RGNX revenue?
    REGENXBIO Inc. (RGNX) reported $153.91M of revenue for the twelve months ended Sep 30, 2026. That is down 4.6% from the year before. Revenue for fiscal 2025 was $170.44M.
  • Is RGNX profitable?
    No. REGENXBIO Inc. reported a net loss of $175.23M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does RGNX have?
    REGENXBIO Inc. reported $95.80M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does RGNX stock trade?
    REGENXBIO Inc. (RGNX) is listed on NASDAQ.
  • What sector and industry is RGNX in?
    REGENXBIO Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
  • When did REGENXBIO Inc. go public?
    REGENXBIO Inc. (RGNX) completed its IPO in 2015.
  • What are analysts saying about RGNX?
    Across the last 8 analyst actions on REGENXBIO Inc., there were 0 upgrades and 2 downgrades. The most recent action was from Mizuho: Outperform with a $22.00 price target on 2026-10-05. Recent price targets range from $12.00 to $38.00.
  • What companies are similar to RGNX?
    Notable peers in the same industry include FDMT (4D Molecular Therapeutics Inc.), RCKT (Rocket Pharmaceuticals Inc.), RARE (Ultragenyx Pharmaceutical Inc.), OCGN (Ocugen Inc.), SRPT (Sarepta Therapeutics Inc.). Compare RGNX side-by-side with any of them on Quantisnow.
  • How can I track RGNX on Quantisnow?
    Quantisnow aggregates REGENXBIO Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RGNX to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change